37th Annual Clinical Hematology & Oncology Conference Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Ali None N/A N/A Andrey None N/A N/A Arnold None N/A N/A Bhangoo None N/A N/A Bollin None N/A N/A Botta None N/A N/A Ariad, Arog, Astellas, Daiichi Sankyo Company, Pfizer, Inc., Grant Research Support Celator Cortes Ariad, Novartis Pharmaceutical Corporation, Daiichi Sankyo Consulting Fees Consultant Company, Pfizer, Inc. Costantini None N/A N/A Bayer Pharmaceuticals, Inc., Consulting Fees Consultant Sirtex Medical Daiichi Sankyo, Keryx Eng Grant Research Support Biopharmaceuticals, Inc. Genentech Inc. Honorarium Speakers Bureau Finkelstein None N/A N/A Daiichi Sankyo Company, Ltd., Bayer, Janssen Pharmaceuticals, Research Support Principal Investigator Inc. Garcia Bristol-Myers Squibb, Pfizer, Service on External Honorarium Inc., grant review panels Service on Advisory Boehringer-Ingelheim Honorarium Board Research to Practice, Med Honoraria Speake’s Bureau Learning Group Ionis Pharmaceuticals, Prothena Corporation, Annexon Biosciences, Novartis Grant Research Support Gertz Pharmaceutical Corporation, Alnylam Pharmaceuticals Celgene Corporation, National Cancer Institute of Frederick, Honoraria Speaker/Consultant Sandoz Inc (a Novartis Company), GlaxoSmithKline, plc Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Guyton None N/A N/A Hutchins None N/A N/A Iyengar None N/A N/A Kelton None N/A N/A Speakers Bureau Honoraria Novocure Investigator Initiated Research Funding Kesari Clinical Trial PI Eli Lilly, Merck, Epicentrix, Research Funding Clinical Trial PI Kadmon Speaking (unbranded Celgene Corporation Honorarium talks; not “speakers bureau”) LeBlanc Epi-Q, Inc., Janssen Pharmaceuticals, Inc., Pfizer, Honorarium Consulting Inc., Flatiron Seattle Genetics Research Grant Research Study Investigator on Clinical Litzow Amgen Research Funding Trials Ma Baxalta, Novo Nordisk Honorarium and Travel Advisory Board Mason None N/A N/A Martinez None N/A N/A Pharmacyclics, Gilead Sciences, Inc., AbbVie, Acerta, TG Grant Research Support Mato Therapeutics Celgene Corporation, Genentech, Consulting Fees Consultant Pharmacyclics, Gilead Sciences Consulting x1 (4- Boehringer-Ingelheim, Janssen 2016), Consulting x1 Moll Pharmaceuticals, Inc., Stago Consulting Fee (6-2016), Consulting Diagnostica x1 (4-2016) Puma Biotechnology, Inc. Consulting Fees DSMB Mortimer Novartis Pharmaceutical Speaker’s Bureau Honorarium Corporation (spouse) Nixon None N/A N/A O’Regan Biotheranostics Consulting Fee Advisor Funding for consultative Instrumentation Laboratory Consultant Ortel participation Stago Diagnostica Research Support Research Testing Oktay None N/A N/A Association of Community Lead Research Grant Cancer Centers Consultant Osarogiagbon Eli Lilly Consultant fees Consultant Roche, Genentech Honorarium Speaker Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Reeves Incyte Corporation Honorarium Advisory Board Sabatini None N/A N/A Sanft Biotheranostics Honorarium Media Opportunity Celgene Corporation, Incyte Corporation, Seattle Genetics, Saven Speaker Fee Speaker Teva Pharmaceutical Industries, Takeda Pharmaceuticals, Inc. Stanton None N/A N/A Clinical Trial Design Janssen Research Funding Advisory Board Streiff Janssen, Boehringer-Ingelheim Research Funding PI CSL Behring, Bio2Medical Honorarium Data Safety Monitoring Board Celgene Corporation, Gilead Xavier Sciences Inc., Incyte Corporation, Honorarium Speaker/Advisor Seattle Genetics Genentech/Roche, GlaxoSmithKline, Gilead Sciences, Inc., Celgene Corporation, Janssen, Hospira, Amgen, Takeda Pharmaceuticals, Honorarium Consulting Inc., Novartis, Nanostring Zelnetz Technology, Portola Pharmaceuticals, Adaptive Biotech GlaxoSmithKline, Janssen, Roche, Gilead Sciences, Inc., Research Consulting Bristol Myers Squibb Scripps Conference None N/A N/A Services & CME Glossary of Terms Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship. .